ETV6-RUNX1 t(12;21) DF

Intended Use

The most common aberration in pediatric B-cell ALL is t(12;21)(p13;q22) with an incidence of about 25%, compared to <5% in adults. The result of this reciprocal translocation is an ETV6/RUNX1 fusion gene. Scientific data suggest that ETV6/RUNX1 is already established prenatally, but additional chromosomal aberrations are necessary for the development of ALL postnatally. The ETV6/RUNX1 fusion gene is transcriptionally active and is dysregulating a cascade of downstream genes. One study has shown, that all positive t(12;21) cases harbored the ETV6/RUNX1 fusion gene but not the reciprocal gene. This suggests, that ETV6/RUNX1 is involved in the manifestation of ALL, but not RUNX1/ETV6.

Patient Preparation
  • Sample collection: Non-diluted bone marrow aspirate. Collect in a sodium heparinized Vacutainer.
  • Specimen preparation: Do not freeze or expose to extreme temperatures.
  • Bone Marrow: Transfer 3 mL bone marrow to a Green (Sodium Heparin). (Min: 1 mL)
  • Whole Blood: Transport 5 mL whole blood. (Min: 2 mL)
  • Storage/Transport Temperature: Room temperature.
  • Unacceptable Conditions: Frozen specimens. Clotted specimens.
  • Remarks:
  • Stability: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Methodology

Fluorescence in situ Hybridization (FISH)

Sample received to report Turnaround time (TAT)

3 working days

Reference Interval

————-

Interpretive Data

The most recent WHO classification of Tumours of Hematopoietic and Lymphoid Tissues (Revised 5th edition) is used for interpretation criteria for evaluation.

Resources

Sample Reports